H.C. Wainwright lowered the firm’s price target on Splash Beverage (SBEV) to 50c from $1 and keeps a Buy rating on the shares ...
The Company clarified that they are not obligated to sell any Shares under this agreement. H.C. Wainwright & Co., LLC will act to sell the Shares based on electroCore’s instructions and within the ...
H.C. Wainwright maintains a Buy rating and 12-month price target of $11 on CollPlant (CLGN) shares after the company reported Q3 results and ...
H.C. Wainwright has recently initiated Quantum-Si Inc (QSI) stock to Buy rating, as announced on December 8, 2023, according to Finviz. Earlier, on September 25, 2023, Canaccord Genuity had reduced ...
H.C. Wainwright raised the firm’s price target on Iris Energy (IREN) to $16 from $13 and keeps a Buy rating on the shares. The company is ...
H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Alector (ALEC) to $7 from $35 and keeps a Buy rating ...
H.C. Wainwright has recently reduced Eyenovia Inc (EYEN) stock to Neutral rating, as announced on November 18, 2024, according to Finviz. Earlier, on March 1, 2021, Northland Capital had initiated the ...
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Regenxbio (RGNX) to $36 from $40 and keeps a Buy rating on the shares after the ...
H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $49 from $43 and keeps a Buy rating on the shares. Acoramidis received regulatory approval with the label underscoring ...
H.C. Wainwright analyst Douglas Tsao reiterates a Buy rating on Biohaven (BHVN) after taldefgrobep alfa missed in Phase 3 for spinal muscular atrophy. Perhaps the more important commercial finding ...
To access the live webcast of the fireside chat, please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a ...
Phunware (NASDAQ:PHUN) shares retreated 11% in Tuesday late morning trading after H.C. Wainwright & Co. downgraded the application software company to Neutral from Buy, as analyst Scott Buck ...